Oct 2, 2020 | Webinar

Interested in the place of urinary markers in NMIBC follow-up?

Watch a webinar by Prof. Fred Witjes

On Thursday 24 September 2020, Nucleix, Israel and Oncotest-Rhenium, Israel organised the webinar “Follow-up of NMIBC, Including the Place of Urinary Markers”. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands and 15 minutes Q&A, and was chaired by Dr. Dov Engelstein, Chairman of the Israel Association of Urology (IAU), and Dr. Ran Katz, Associate in the Israel Association of Urology (IAU).

Watch this webinar to learn more about:

  • The current guidelines on treatment and follow-up of Non Muscle-Invasive Bladder Cancer (NMIBC)
  • The pitfalls of the current follow-up procedures
  • Urinary markers in follow-up and promising results from clinical studies
  • The benefits of urinary markers in general and during the COVID-19 pandemic

Moreover, Prof. Dr. Fred Witjes provided insights on how he implements the Bladder EpiCheck® urine test in his clinical practice.

Other updates

Webinar on Bladder EpiCheck®, for NMIBC monitoring

On Tuesday October 6th  2020, Nucleix, Israel and Palex Medical, Spain organised the webinar “Bladder EpiCheck®, for accurate, non-invasive bladder cancer monitoring”. Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands,...

read more